Home Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation
Article
Licensed
Unlicensed Requires Authentication

Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation

  • Rahil Eftekhari , Stacy G. de Lima , Yu Liu , Koichiro Mihara , Mahmoud Saifeddine , Farshid Noorbakhsh , Isobel A. Scarisbrick and Morley D. Hollenberg EMAIL logo
Published/Copyright: June 20, 2018
Biological Chemistry
From the journal Biological Chemistry Volume 399 Issue 9

Abstract

We propose that in the microenvironment of inflammatory tissues, including tumours, extracellular proteinases can modulate cell signalling in part by regulating proteinase-activated receptors (PARs). We have been exploring this mechanism in a variety of inflammation and tumour-related settings that include tumour-derived cultured cells from prostate and bladder cancer, as well as immune inflammatory cells that are involved in the pathology of inflammatory diseases including multiple sclerosis. Our work showed that proteinase signalling via the PARs affects prostate and bladder cancer-derived tumour cell behaviour and can regulate calcium signalling in human T-cell and macrophage-related inflammatory cells as well as in murine splenocytes. Further, we found that the tumour-derived prostate cancer cells and immune-related cells (Jurkat, THP1, mouse splenocytes) can produce PAR-regulating proteinases (including kallikreins: kallikrein-related peptidases), that can control tissue function by both a paracrine and autocrine mechanism. We suggest that this PAR-driven signalling process involving secreted microenvironment proteinases can play a key role in cancer and inflammatory diseases including multiple sclerosis.

Keywords: bladder cancer; microenvironment proteinases; multiple sclerosis; prostate cancer; proteinase-activated receptors (PARs); T-cells/macrophages/splenocytes

Funding source: National Institute of Neurological Disorders and Stroke

Award Identifier / Grant number: R01NS052741

Funding statement: Supported by the Telus Calgary Ride for Dad-Prostate Cancer Fight Foundation, the Edmonton Janssen Research Foundation and the Canadian Institutes of Health Research (CIHR). These studies were also supported in part by the National Institute of Neurological Disorders and Stroke, Funder Id: 10.13039/100000065, Grant Number: R01NS052741 and Funder Id: 10.13039/100001770, Grant Number: RG3367 from the National Multiple Sclerosis Society to I.A.S. The expert assistance of the Snyder Institute live cell imaging facility is also gratefully acknowledged.

  1. Funding: The Johnson & Johnson Alberta Health Innovation Partnership (JAHIP) Prostate Cancer Research Fund/University Hospital Foundation, University of Alberta Hospital, Funder Id: Grant Number: Prostate Proteases, Protease-Activated Receptors. Canadian Institutes of Health Research, Funder Id: 10.13039/501100000024, Grant Number: 201603PJT-363434-PJT-CBBA-13135.

References

Adams, M.N., Ramachandran, R., Yau, M.K., Suen, J.Y., Fairlie, D.P., Hollenberg, M.D., and Hooper, J.D. (2011). Structure, function and pathophysiology of protease activated receptors. Pharmacol. Ther. 130, 248–282.10.1016/j.pharmthera.2011.01.003Search in Google Scholar PubMed

Bando, Y., Hagiwara, Y., Suzuki, Y., Yoshida, K., Aburakawa, Y., Kimura, T., Murakami, C., Ono, M., Tanaka, T., Jiang, Y.P., et al. (2018). Kallikrein 6 secreted by oligodendrocytes regulates the progression of experimental autoimmune encephalomyelitis. Glia 66, 359–378.10.1002/glia.23249Search in Google Scholar PubMed

Bar-Shavit, R., Maoz, M., Yongjun, Y., Groysman, M., Dekel, I., and Katzav, S. (2002). Signalling pathways induced by protease-activated receptors and integrins in T cells. Immunology 105, 35–46.10.1046/j.0019-2805.2001.01351.xSearch in Google Scholar PubMed PubMed Central

Bernett, M.J., Blaber, S.I., Scarisbrick, I.A., Dhanarajan, P., Thompson, S.M., and Blaber, M. (2002). Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277, 24562–24570.10.1074/jbc.M202392200Search in Google Scholar PubMed

Blaber, S.I., Scarisbrick, I.A., Bernett, M.J., Dhanarajan, P., Seavy, M.A., Jin, Y., Schwartz, M.A., Rodriguez, M., and Blaber, M. (2002). Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41, 1165–1173.10.1021/bi015781aSearch in Google Scholar PubMed

Blaber, S.I., Ciric, B., Christophi, G.P., Bernett, M.J., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. (2004). Targeting kallikrein 6 proteolysis attenuates CNS inflammatory disease. FASEB J. 18, 920–922.10.1096/fj.03-1212fjeSearch in Google Scholar PubMed

Borgoño, C.A. and Diamandis, E.P. (2004). The emerging roles of human tissue kallikreins in cancer. Nat. Rev. Cancer 4, 876–890.10.1038/nrc1474Search in Google Scholar PubMed

Burger, M.M. (1970). Proteolytic enzymes initiating cell division and escape from contact inhibition of growth. Nature 227, 170–171.10.1038/227170a0Search in Google Scholar PubMed

Carney, D.H. and Cunningham, D.D. (1977). Initiation of check cell division by trypsin action at the cell surface. Nature 268, 602–606.10.1038/268602a0Search in Google Scholar PubMed

Carney, D.H. and Cunningham, D.D. (1978). Transmembrane action of thrombin initiates chick cell division. J. Supramol. Struct. 9, 337–350.10.1002/jss.400090305Search in Google Scholar PubMed

Chen, L.B. and Buchanan, J.M. (1975). Mitogenic activity of blood components. I. Thrombin and prothrombin. Proc. Natl. Acad. Sci. USA 72, 131–135.10.1073/pnas.72.1.131Search in Google Scholar

Coughlin, S.R. (2000). Thrombin signalling and protease-activated receptors. Nature 407, 258–264.10.1038/35025229Search in Google Scholar

Cuatrecasas, P. (1969). Interaction of insulin with the cell membrane: the primary action of insulin. Proc. Natl. Acad. Sci. USA 63, 450–457.10.1073/pnas.63.2.450Search in Google Scholar

Cuatrecasas, P. (1971). Properties of the insulin receptor of isolated fat cell membranes. J. Biol. Chem. 246, 7265–7274.10.1016/S0021-9258(19)45882-1Search in Google Scholar

Gleeson, E.M., O’Donnell, J.S., Hams, E., Ní Áinle, F., Kenny, B.A., Fallon, P.G., and Preston, R.J. (2014). Activated factor X signaling via protease-activated receptor 2 suppresses pro-inflammatory cytokine production from lipopolysaccharide-stimulated myeloid cells. Haematology 99, 185–193.10.3324/haematol.2013.086918Search in Google Scholar

Hansen, K.K., Saifeddine, M., and Hollenberg, M.D. (2004). Tethered ligand-derived peptides of proteinase-activated receptor 3 (PAR3) activate PAR1 and PAR2 in Jurkat cells. Immunology 112, 183–190.10.1111/j.1365-2567.2004.01870.xSearch in Google Scholar

Hollenberg, M.D. and Compton, S.J. (2002). International Union of Pharmacology. XXVIII. Proteinase-activated receptors. Pharmacol. Rev. 54, 203–217.10.1124/pr.54.2.203Search in Google Scholar

Hollenberg, M.D. and Cuatrecasas, P. (1973). Epidermal growth factor: receptors in human fibroblasts and modulation of action by cholera toxin. Proc. Natl. Acad. Sci. USA 70, 2964–2968.10.1073/pnas.70.10.2964Search in Google Scholar

Kang, K.-S., Tae, J., Lee, Y.-M., Kim, B.S., Moon, W.S., and Kim, D.K. (2005). Protease-activated receptor 2 is associated with activation of human macrophage cell line THP-1. Immune Network 5, 193–198.10.4110/in.2005.5.4.193Search in Google Scholar

Kawabata, A., Saifeddine, M., Al-Ani, B., Leblond, L., and Hollenberg, M.D. (1999). Evaluation of proteinase-activated receptor-1 (PAR1) agonists and antagonists using a cultured cell receptor desensitization assay: activation of PAR2 by PAR1-targeted ligands. J. Pharmacol. Exp. Ther. 288, 358–370.10.1016/S0022-3565(24)37961-3Search in Google Scholar

Kono, T. and Barham, F.W. (1971). Insulin-like effects of trypsin on fat cells. Localization of the metabolic steps and the cellular site affected by the enzyme. J. Biol. Chem. 246, 6204–6209.10.1016/S0021-9258(18)61776-4Search in Google Scholar

Mari, B., Guerin, S., Far, D.F., Breitmayer, J.P., Belhacene, N., Peyron, J.F., Rossi, B., and Auberger, P. (1996). Thrombin and trypsin-induced Ca2+ mobilization in human T cell lines through interaction with different protease-activated receptors. FASEB J. 10, 309–316.10.1096/fasebj.10.2.8641564Search in Google Scholar PubMed

Mihara, K., Ramachandran, R., Renaux, B., Saifeddine, M., and Hollenberg, M.D. (2013). Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). J. Biol. Chem. 288, 32979–32990.10.1074/jbc.M113.483123Search in Google Scholar PubMed PubMed Central

Mihara, K., Ramachandran, R., Saifeddine, M., Hansen, K.K., Renaux, B., Polley, D., Gibson, S., Vanderboor, C., and Hollenberg, M.D. (2016). Thrombin-mediated direct activation of proteinase-activated receptor-2: another target for thrombin signaling. Mol. Pharmacol. 89, 606–614.10.1124/mol.115.102723Search in Google Scholar PubMed

Nargis, T., Kumar, K., Ghosh, A.R., Sharma, A., Rudra, D., Sen, D., Chakrabarti, S., Mukhopadhyay, S., Ganguly, D., and Chakrabarti, P. (2017). KLK5 induces shedding of DPP4 from circulatory Th17 cells in type 2 diabetes. Mol. Metab. 6, 1529–1539.10.1016/j.molmet.2017.09.004Search in Google Scholar PubMed PubMed Central

Noorbakhsh, F., Tsutsui, S., Vergnolle, N., Boven, L.A., Shariat, N., Vodjgani, M., Warren, K.G., Andrade-Gordon, P., Hollenberg, M.D., and Power, C. (2006). Proteinase-activated receptor 2 modulates neuroinflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. J. Exp. Med. 203, 425–435.10.1084/jem.20052148Search in Google Scholar PubMed PubMed Central

Nylander-Lundqvist, E. and Egelrud, T. (1997). Formation of active IL-1β from pro-IL-1 beta catalyzed by stratum corneum chymotryptic enzyme in vitro. Acta. Derm. Venereol. 77, 203–206.10.2340/0001555577203206Search in Google Scholar

Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Tea, I., Blaber, M., Blaber, S.I., Scarisbrick, I., Andrade-Gordon, P., Cottrell, G.S., Bunnett, N.W., et al. (2006a). Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 281, 32095–32112.10.1074/jbc.M513138200Search in Google Scholar PubMed

Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Vergnolle, N., Tea, I., Diamandis, E.P., and Hollenberg, M.D. (2006b). Proteinase-mediated cell signalling: targeting proteinase-activated receptors (PARs) by kallikreins and more. Biol. Chem. 387, 677–685.10.1515/BC.2006.086Search in Google Scholar PubMed

Pampalakis, G., Sykioti, V.S., Ximerakis, M., Stefanakou-Kalakou, I., Melki, R., Vekrellis, K., and Sotiropoulou, G. (2017). KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. Oncotarget 8, 14502–14515.10.18632/oncotarget.13264Search in Google Scholar PubMed PubMed Central

Panos, M., Christophi, G.P., Rodriguez, M., and Scarisbrick, I.A. (2014). Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response. Biol. Chem. 395, 1063–1073.10.1515/hsz-2014-0141Search in Google Scholar PubMed PubMed Central

Prassas, I., Eissa, A., Poda, G., and Diamandis, E.P. (2015). Unleashing the therapeutic potential of human kallikrein-related serine proteases. Nat. Rev. Drug Discov. 14, 183–202.10.1038/nrd4534Search in Google Scholar PubMed

Ramachandran, R., Mihara, K., Chung, H., Renaux, B., Lau, C.S., Muruve, D.A., DeFea, K.A., Bouvier, M., and Hollenberg, M.D. (2011). Neutrophil elastase acts as a biased agonist for proteinase-activated receptor-2 (PAR2). J. Biol. Chem. 286, 24638–24648.10.1074/jbc.M110.201988Search in Google Scholar PubMed PubMed Central

Ramachandran, R., Noorbakhsh, F., Defea, K., and Hollenberg, M.D. (2012). Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat. Rev. Drug Discov. 11, 69–86.10.1038/nrd3615Search in Google Scholar PubMed

Ramachandran, R., Altier, C., Oikonomopoulou, K., and Hollenberg, M.D. (2016). Proteinases, their extracellular targets, and inflammatory signaling. Pharmacol. Rev. 68, 1110–1142.10.1124/pr.115.010991Search in Google Scholar PubMed

Rieser, P. (1967). The insulin-like action of pepsin and pepsinogen. Acta. Endocrinol. (Copenh.) 54, 375–379.10.1530/acta.0.0540375Search in Google Scholar PubMed

Rieser, P. and Rieser, C.H. (1964). Anabolic responses of diaphragm muscle to insulin and to other pancreatic proteins. Proc. Soc. Exp. Biol. Med. 116, 669–671.10.3181/00379727-116-29339Search in Google Scholar PubMed

Scarisbrick, I.A., Towner, M.D., and Isackson, P.J. (1997). Nervous system-specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J. Neurosci. 17, 8156–8168.10.1523/JNEUROSCI.17-21-08156.1997Search in Google Scholar

Scarisbrick, I.A., Blaber, S.I., Lucchinetti, C.F., Genain, C.P., Blaber, M., and Rodriguez, M. (2002). Activity of a newly identified serine protease in CNS demyelination. Brain 125, 1283–1296.10.1093/brain/awf142Search in Google Scholar PubMed

Scarisbrick, I.A., Blaber, S.I., Tingling, J.T., Rodriguez, M., Blaber, M., and Christophi, G.P. (2006). Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J. Neuroimmunol. 178, 167–176.10.1016/j.jneuroim.2006.05.022Search in Google Scholar PubMed

Scarisbrick, I.A., Linbo, R., Vandell, A.G., Keegan, M., Blaber, S.I., Blaber, M., Sneve, D., Lucchinetti, C.F., Rodriguez, M., and Diamandis, E.P. (2008). Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol. Chem. 389, 739–745.10.1515/BC.2008.085Search in Google Scholar PubMed PubMed Central

Scarisbrick, I.A., Yoon, H., Panos, M., Larson, N., Blaber, S.I., Blaber, M., and Rodriguez, M. (2012). Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis. Brain Pathol. 22, 709–722.10.1111/j.1750-3639.2012.00577.xSearch in Google Scholar PubMed PubMed Central

Sefton, B.M. and Rubin, H. (1970). Release from density dependent growth inhibition by proteolytic enzymes. Nature 227, 843–845.10.1038/227843a0Search in Google Scholar

Shaw, J.L. and Diamandis, E.P. (2007). Distribution of 15 human kallikreins in tissues and biological fluids. Clin. Chem. 53, 1423–1432.10.1373/clinchem.2007.088104Search in Google Scholar

Shoelson, S.E., White, M.F., and Kahn, C.R. (1988). Tryptic activation of the insulin receptor. Proteolytic truncation of the α-subunit releases the β-subunit from inhibitory control. J. Biol. Chem. 263, 4852–4860.10.1016/S0021-9258(18)68864-7Search in Google Scholar

Sotiropoulou, G. and Pampalakis, G. (2010). Kallikrein-related peptidases: bridges between immune functions and extracellular matrix degradation. Biol. Chem. 391, 321–331.10.1515/bc.2010.036Search in Google Scholar

Sotiropoulou, G., Pampalakis, G., and Diamandis, E.P. (2009). Functional roles of human kallikrein-related peptidases. J. Biol. Chem. 284, 32989–32994.10.1074/jbc.R109.027946Search in Google Scholar

Steven, R., Crilly, A., Lockhart, J.C., Ferrell, W.R., and McInnes, I.B. (2013). Proteinase-activated receptor-2 modulates human macrophage differentiation and effector function. Innate Immun. 19, 663–672.10.1177/1753425913479984Search in Google Scholar

Vergnolle, N., Hollenberg, M.D., Sharkey, K.A., and Wallace, J.L. (1999). Characterization of the inflammatory response to proteinase-activated receptor-2 (PAR2)-activating peptides in the rat paw. Br. J. Pharmacol. 127, 1083–1090.10.1038/sj.bjp.0702634Search in Google Scholar

Vu, T.K., Hung, D.T., Wheaton, V.I., and Coughlin, S.R. (1991). Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 64, 1057–1068.10.1016/0092-8674(91)90261-VSearch in Google Scholar

Wilson, S.R., Gallagher, S., Warpeha, K., and Hawthorne, S.J. (2004). Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate 60, 168–174.10.1002/pros.20047Search in Google Scholar PubMed

Ximerakis, M., Pampalakis, G., Roumeliotis, T.I., Sykioti, V.S., Garbis, S.D., Stefanis, L., Sotiropoulou, G., and Vekrellis, K. (2014). Resistance of naturally secreted α-synuclein to proteolysis. FASEB J. 28, 3146–3158.10.1096/fj.13-245852Search in Google Scholar PubMed

Yamasaki, K., Schauber, J., Coda, A., Lin, H., Dorschner, R.A., Schechter, N.M., Bonnart, C., Descargues, P., Hovnanian, A., and Gallo, R.L. (2006). Kallikrein-mediated proteolysis regulates the antimicrobial effects of cathelicidins in skin. FASEB J. 20, 2068–2080.10.1096/fj.06-6075comSearch in Google Scholar PubMed

Yao, C., Karabasil, M.R., Purwanti, N., Li, X., Akamatsu, T., Kanamori, N., and Hosoi, K. (2006). Tissue kallikrein mK13 is a candidate processing enzyme for the precursor of interleukin-1beta in the submandibular gland of mice. J. Biol. Chem. 281, 7968–7976.10.1074/jbc.M507705200Search in Google Scholar PubMed

Yoon, H. and Scarisbrick, I.A. (2016). Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis. Biol. Chem. 397, 1277–1286.10.1515/hsz-2016-0239Search in Google Scholar PubMed PubMed Central

Yoon, H., Blaber, S.I., Li, W., Scarisbrick, I.A., and Blaber, M. (2013). Activation profiles of human kallikrein-related peptidases by matrix metalloproteinases. Biol. Chem. 394, 137–147.10.1515/hsz-2012-0249Search in Google Scholar PubMed PubMed Central

Received: 2018-01-01
Accepted: 2018-06-08
Published Online: 2018-06-20
Published in Print: 2018-09-25

©2018 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Highlight: The 7th International Symposium on Kallikreins and Kallikrein-Related Peptidases
  3. Obituary
  4. Manfred Schmitt (1947–2018)
  5. Functional interrelationships between the kallikrein-related peptidases family and the classical kinin system in the human neutrophil
  6. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer
  7. Kallikrein-related peptidases in lung diseases
  8. The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer
  9. Mining human cancer datasets for kallikrein expression in cancer: the ‘KLK-CANMAP’ Shiny web tool
  10. Specificity profiling of human trypsin-isoenzymes
  11. Activation and activity of glycosylated KLKs 3, 4 and 11
  12. Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation
  13. Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms
  14. Kallikrein-related peptidase 5 and seasonal influenza viruses, limitations of the experimental models for activating proteases
  15. Novel splice variants of the human kallikrein-related peptidases 11 (KLK11) and 12 (KLK12), unraveled by next-generation sequencing technology
  16. Insights into the activity control of the kallikrein-related peptidase 6: small-molecule modulators and allosterism
  17. Kallikrein-related peptidase 14 is the second KLK protease targeted by the serpin vaspin
  18. Profiling system for skin kallikrein proteolysis applied in gene-deficient mouse models
  19. Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1
  20. Kallikrein-related peptidase 7 overexpression in melanoma cells modulates cell adhesion leading to a malignant phenotype
  21. KLK5, a novel potential suppressor of vaginal carcinogenesis
https://doi.org/10.1515/hsz-2018-0001
Keywords for this article
bladder cancer; microenvironment proteinases; multiple sclerosis; prostate cancer; proteinase-activated receptors (PARs); T-cells/macrophages/splenocytes

Articles in the same Issue

  1. Frontmatter
  2. Highlight: The 7th International Symposium on Kallikreins and Kallikrein-Related Peptidases
  3. Obituary
  4. Manfred Schmitt (1947–2018)
  5. Functional interrelationships between the kallikrein-related peptidases family and the classical kinin system in the human neutrophil
  6. Overview of tissue kallikrein and kallikrein-related peptidases in breast cancer
  7. Kallikrein-related peptidases in lung diseases
  8. The miRNA-kallikrein interaction: a mosaic of epigenetic regulation in cancer
  9. Mining human cancer datasets for kallikrein expression in cancer: the ‘KLK-CANMAP’ Shiny web tool
  10. Specificity profiling of human trypsin-isoenzymes
  11. Activation and activity of glycosylated KLKs 3, 4 and 11
  12. Microenvironment proteinases, proteinase-activated receptor regulation, cancer and inflammation
  13. Kallikrein-related peptidase 6 orchestrates astrocyte form and function through proteinase activated receptor-dependent mechanisms
  14. Kallikrein-related peptidase 5 and seasonal influenza viruses, limitations of the experimental models for activating proteases
  15. Novel splice variants of the human kallikrein-related peptidases 11 (KLK11) and 12 (KLK12), unraveled by next-generation sequencing technology
  16. Insights into the activity control of the kallikrein-related peptidase 6: small-molecule modulators and allosterism
  17. Kallikrein-related peptidase 14 is the second KLK protease targeted by the serpin vaspin
  18. Profiling system for skin kallikrein proteolysis applied in gene-deficient mouse models
  19. Evidence that cell surface localization of serine protease activity facilitates cleavage of the protease activated receptor CDCP1
  20. Kallikrein-related peptidase 7 overexpression in melanoma cells modulates cell adhesion leading to a malignant phenotype
  21. KLK5, a novel potential suppressor of vaginal carcinogenesis
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 25.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/hsz-2018-0001/html
Scroll to top button